A longitudinal international multicenter study to evaluate the incidence of radiological vertebral fractures in patients with Acromegaly treated with Pegvisomant and Pasireotide LAR
Latest Information Update: 25 Oct 2019
At a glance
- Drugs Pasireotide (Primary) ; Pegvisomant (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
Most Recent Events
- 15 Oct 2019 Results evaluating Incidence of Vertebral Fractures in patients with acromegaly published in the Journal of Clinical Endocrinology and Metabolism
- 07 May 2019 New trial record
- 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society